PMID: 9422557Jan 9, 1998Paper

Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06

International Journal of Radiation Oncology, Biology, Physics
C B ScottWalter Curran

Abstract

The recursive partitioning analysis (RPA) classes for malignant glioma patients were previously established using data on over 1500 patients entered on Radiation Therapy Oncology Group (RTOG) clinical trials. The purpose of the current analysis was to validate the RPA classes with a new dataset (RTOG 90-06), determine the predictive power of the RPA classes, and establish the usefulness of the database norms for the RPA classes. There are six RPA classes for malignant glioma patients that comprise distinct groups of patients with significantly different survival outcome. RTOG 90-06 is a randomized Phase III study of 712 patients accrued from 1990 to 1994. The minimum potential follow-up is 18 months. The treatment arms were combined for the purpose of this analysis. There were 84, 13, 105, 240, 150, and 23 patients in the RPA Classes I-VI from RTOG 90-06, respectively. The median survival times (MST) and 2-year survival rates for the six RPA classes in RTOG 90-06 are compared to those previously published. The MST and 2-year survival rates for the RTOG RPA classes were within 95% confidence intervals of the 90-06 estimates for Classes I, III, IV, and V. The RPA classes explained 43% of the variation (squared error loss). By com...Continue Reading

References

May 1, 1990·Statistics in Medicine·E L Korn, R Simon
Dec 20, 1995·Journal of the National Cancer Institute·S KirbyG Cairncross

❮ Previous
Next ❯

Citations

Apr 9, 2009·Cancer Chemotherapy and Pharmacology·Patrick D BeauchesneC Carnin
Jul 11, 2013·European Radiology·Roberto Sanz-RequenaGracián García-Martí
Oct 20, 2011·Amino Acids·Satoru TakeuchiNariyoshi Shinomiya
Dec 6, 2006·Journal of Neuro-oncology·Susan ChangUNKNOWN American Association of Neurological Surgeons and Congress of Neurological Surgeons (AANS/CNS)
Mar 31, 2009·Journal of Neuro-oncology·Nader PouratianJason P Sheehan
Oct 11, 2011·Journal of Neuro-oncology·Matthew KoshyBridget J McCarthy
Jun 13, 2012·Journal of Neuro-oncology·Christopher A BarkerFabio M Iwamoto
Sep 3, 2010·Targeted Oncology·Silvia Hofer, Andrew B Lassman
Oct 26, 2005·Current Treatment Options in Oncology·Volker W Stieber, Thomas L Ellis
Dec 21, 2000·Current Oncology Reports·M R Gilbert
Jun 22, 2005·Current Treatment Options in Neurology·Mark R Gilbert, Monica Loghin
Apr 17, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ping WeiQian Shi
Apr 26, 2005·Cancer Treatment Reviews·Sara LonardiAlba A Brandes
May 12, 2005·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Corrie A M MarijnenEd M Noordijk
Jun 19, 2003·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J J McAleeseMichael Brada
May 31, 2001·International Journal of Radiation Oncology, Biology, Physics·A KatzE A Strom
Apr 17, 2002·International Journal of Radiation Oncology, Biology, Physics·Rafal TarnawskiTeresa Krupska
May 12, 2004·Nature Reviews. Drug Discovery·Jeremy N Rich, Darell D Bigner
Jun 16, 2005·Journal of the National Cancer Institute·Federico Cappuzzo
Sep 4, 2003·The Cancer Journal·John B Fiveash, Sharon A Spencer
Sep 27, 2006·Anti-cancer Drugs·Sith Sathornsumetee, Jeremy N Rich
Feb 7, 2007·American Journal of Clinical Oncology·Robert A LustigWalter J Curran
Sep 1, 2007·Anti-cancer Drugs·Riccardo SoffiettiElisa Trevisan
Oct 2, 2007·Current Opinion in Oncology·Dieta Brandsma, Martin J van den Bent
Oct 14, 2009·American Journal of Clinical Oncology·Randall J KimpleDavid E Morris
Feb 1, 2012·The Cancer Journal·Jiangbing ZhouW Mark Saltzman
Oct 5, 2006·Neuro-oncology·Ingeborg BosmaMartin Klein
Mar 24, 2009·Journal of Neurosurgery·Brian J WilliamsGanesh Rao

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
Roger StuppNational Cancer Institute of Canada Clinical Trials Group
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
René-Olivier MirimanoffRoger Stupp
© 2021 Meta ULC. All rights reserved